54734-85-9

Usage

General Description

2-Amino-5-nitrobenzene-1-sulfonamide is a chemical compound that belongs to the class of sulfonamides. It is an organic compound with a molecular formula C6H6N4O4S, and it is commonly used as a bacterial inhibitor in the field of pharmacology. 2-aMino-5-nitrobenzene-1-sulfonaMide inhibits the bacterial enzyme dihydropteroate synthase, thereby preventing the synthesis of folic acid, which is essential for bacterial growth. 2-Amino-5-nitrobenzene-1-sulfonamide is also used as an intermediate in the synthesis of pharmaceuticals and dyes. However, it is important to handle 2-aMino-5-nitrobenzene-1-sulfonaMide with caution, as it is considered hazardous and has the potential to cause skin and eye irritation.

Upstream product

• 20628-33-5 2-Amino-5-nitro-benzolsulfonylchlorid 
• 30693-53-9 2-amino-5-nitrobenzenesulfonic acid sodium salt 
• 96-75-3 2-amino-5-nitro-benzenesulfonic acid 
• 96-73-1 2-chloro-5-nitro-benzenesulfonic acid 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 5455-59-4 2-Nitrobenzenesulfonamide 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 946-30-5 2-chloro-5-nitrobenzenesulphonic acid sodium salt 
• 100-00-5 4-chlorobenzonitrile 
• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 96-72-0 2-chloro-5-nitrobenzenesulfonamide 
• 13338-00-6 2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 

Downstream Products

• 20896-44-0 2,5-diaminobenzenesulfonamide 
• 1312611-37-2 C₁₃H₈N₄O₆S 
• 1312611-38-3 C₁₃H₁₂N₄O₂S 
• 1312609-51-0 C₃₇H₄₈N₈O₁₀S 
• 1370714-06-9 N-[3-(1-benzyl-1H-indol-3-yl)-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methansulfonamide 
• 691361-76-9 2-amino-5-(methanesulfonylamino)benzenesulfonamide 
• 847442-09-5 N-{3-[4-(2-cyclohexylideneethyl)-1-hydroxy-4-methyl-3-oxo-3,4-dihydronaphthalen-2-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide 
• 1056901-19-9 N-{3-[5-(S)-(4-fluoro-benzyl)-8-hydroxy-5-methyl-6-oxo-5,6-dihydro-indolizin-7-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide 
• 1000313-22-3 1-{(3-chloro-4-fluoro-benzyl)-[2-(7-methanesulfonylmethyl-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-amino}-1H-pyrrole-2-carboxylic acid allyl ester 
• 1618673-13-4 N-(4-nitro-2-sulfamoylphenyl)malonamic acid methyl ester 
• 1618673-18-9 N-(4-amino-2-sulfamoylphenyl)malonamic acid methyl ester 
• 1071519-56-6 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6,9-dihydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide 
• 1071522-56-9 (1S,2R,3S,4R)-3-{(3-fluoro-4-methylbenzyl)-[2-(7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)acetyl]amino}bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 1071519-24-8 (1R,2S,7R,8S)-N-{3-[3-(3-chloro-4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide 

Relevant academic research and scientific papers

Synthesis and biological effects of new 3-alkylamino-4H-1,2,4- benzothiadiazine 1,1-dioxides on insulin-secreting cells

3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides with nitro, amino or acetylamino groups in the 7-position have been synthesized in an attempt to discover new tissue-selective K(ATP)-channel openers. The compounds were tested as putative pancreatic β-cells K(ATP)-channel openers by measuring their inhibitory activity on the insulin releasing process. The influence of the substituent in the 7-position on the acidic character (pK(a)) and on biological activity is discussed. The nitrobenzene derivatives were biologically active, but less so than the un-derivatized parent pyridothiadiazine dioxides.

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

A NOVEL PROCESS FOR THE PREPARATION OF N-(4-NITRO-2-SULFAMOYL-PHENYL)-MALONAMIC ACID METHYL ESTER AND N-(4-AMINO-2-SULFAMOYL-PHENYL)-MALONAMIC ACID METHYL ESTER

The present invention provides a novel method for preparing compounds N-(4-nitro-2-sulfamoyl-phenyl)-malonamic acid methyl ester and N-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester, which are novel intermediates for preparing a key intermediate

Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives

This work presents the first structure-based activity prediction model for benzothiadiazines against various genotypes of HCV NS5b polymerase (1a, 1b and 4).The model is a comprehensive workflow of structure-based field template followed by guided docking. The field template was used as a pre-filter and a tool to provide hits in good orientation and position. It was created based on detailed molecular interaction field analysis which includes Topomer CoMFA, grid independent analysis and Superstar. On the other hand, Guided docking was used as a refinement and assessment tool. It was actively directed by two scores: Moldock score as an interaction descriptor (r2 = 0.65) and a template similarity score as a measure for accurate binding-mode compliance. The docking template was based on energy-based pharmacophore analysis. The whole procedure was formulated and tweaked for both screening (ROC of AUC = 0.91) and activity prediction (r2 of 0.8) for the genotype 1a. In order to widen the model scope, linear interaction energy was used as a tool for predicting activities of other genotypes based on the docked ligand poses while mutation binding energy was used to investigate the effect of each amino acid mutation in genotype 4. The model was applied for structure-based fragment hopping by screening a library designed by reaction enumeration. A top scoring hit was used to generate a focused library such that it has lower TPSA than the original class ligands and thus better pharmacokinetic properties. After that, experimental validation was carried out by the synthesis of this library and its biological evaluation which yielded compounds that exhibit EC50 ranging from 1.86 to 23 μM.

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

A METHOD OF INHIBITING HEPATITIS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS

The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-l,4-dihydro-lλ6- benzo[l,2,4]thiadiazin-7-yl} -methanesulfonamide and one or more additional antiviral compounds or pharmaceutical compositions containing such compounds.

4-Hydroxy-5,6-dihydro-1H-pyridin-2-one compounds

The invention is directed to 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives

4,4-Dialkyl-1-hydroxy-3-oxo-3.4-dihydronaphthalene-3-yl benzothiadiazine derivatives were synthesized and evaluated as inhibitors of genotypes 1a and 1b HCV NS5B polymerase. A number of these compounds exhibited potent activity against genotypes 1a and 1b HCV polymerase in both enzymatic and cell culture activities. A representative compound also showed favorable pharmacokinetics in the rat.

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-lH-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.